TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01408511

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mapracorat
Description: Application of the investigational product on the affected skin areas
Study: NCT00985504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 60-120 milligrams (mg) taken once daily (QD) by mouth (po) for 8 weeks; with option for additional 2 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: 10-20 mg taken QD po for 8 weeks; with option for additional 2 weeks.
Study: NCT04651933

Intervention type: GENETIC
Intervention: Homologous recombination deficiency model
Description: A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)

Intervention type: GENETIC
Intervention: Homologous recombination deficiency model
Description: A homologous recombination deficiency (HRD) scoring model based on loss of heterozygosity (LOH)
Study: NCT01882985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lycopene
Description: Given PO
Study: NCT03359616

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanally curable surgical resection
Description: Transanally, the rectal cancer will be mobilized with oncological principle of total mesorectal excision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic total mesorectal excision
Description: Conventionally by laparoscopic surgery, the rectal cancer will be mobilized with oncological principle of total mesorectal excision
Study: NCT04622605

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Trabecular bypass and Schlemm's canal stent
Description: ab interno Microstent placement after cataract surgery
Study: NCT00925704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcitriol
Description: Calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate + Calcitriol
Description: Lanthanum carbonate (1000 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate + Calcitriol
Description: Sevelamer carbonate (2400 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
Study: NCT03837054

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Blood collection and Micronuclei assay on binucleate lymphocytes in culture
Description: The activity of the oncology Department of the North Hospital ensures the quick and easy recruitment of 30 patients over the 10-month inclusion period. The collection of samples will be done in a forward-looking manner during chemotherapy and at different times. The patients will have 4 blood samples of 10 mL carried out during their chemotherapy with a sampling at T0 (before the initiation of chemotherapy), then to T1 (after the first 3 cures), to T2 (after the 6th cure) and to T3 is 5 weeks after the end of the chemo And before the onset of radiation therapy. The samples will be carried out within the Medical Oncology Department of the hospital Nord of Marseille.~We will also perform micronuclei testing on Binucleate lymphocytes in culture. The lymphocyte Micronuclei test reveals structure and number chromosomal damage and allows to reveal clastogenic or eugènes exposures.
Study: NCT02280837

Intervention type: OTHER
Intervention: Determination of plasma GLP-1 level
Description: Determination of GLP-1 level in samples of oral glucose tolerance tests
Study: NCT02850146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-AV-1451
Study: NCT01671228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision aid + patient stories
Description: The Yorkshire dialysis decision aid (YoDDA) plus a set of narratives provided by patients on the treatment options (home and hospital haemodialysis; continuous ambulatory and automated peritoneal dialysis

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decision Aid + values task
Description: The Yorkshire Dialysis decision aid (YoDDA) plus a set of questions to help patients explore what aspects of their life important to them about this decision (values clarification)
Study: NCT01890122

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin
Description: Alogliptin tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin HCl
Description: Metformin HCl capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin and Metformin Fixed-Dose Combination (FDC)
Description: Alogliptin and metformin FDC tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alogliptin Placebo
Description: Alogliptin placebo-matching tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alogliptin Placebo
Description: Alogliptin placebo-matching tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alogliptin Placebo
Description: Alogliptin placebo-matching tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Placebo
Description: Metformin placebo-matching capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Placebo
Description: Metformin placebo-matching capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin Placebo
Description: Metformin placebo-matching capsules
Study: NCT04221516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200mg every 21 days (3 weeks) for up to 18 cycles, from 4 to 12 weeks after the completion of radiotherapy.
Study: NCT01210768

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin+Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal-doxorubicin+Cyclophosphamide
Description: Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
Study: NCT00616967

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel albumin-stabilized nanoparticle formulation
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01229228

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Test
Description: 200-mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen Test
Description: 400-mg (2 x 200-mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn
Description: single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naprosyn
Description: single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: single dose
Study: NCT00268749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glycine
Description: 0.8 g/kg/day
Study: NCT01037309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 SC
Description: Subcutaneous injection, once a week, for five weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 SC
Description: Subcutaneous injection, once a week, for five weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 SC
Description: Subcutaneous injection, once a week, for five weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 SC
Description: Subcutaneous injection, once a week, for five weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 SC
Description: Subcutaneous injection, once a week, for five weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 SC
Description: Subcutaneous injection, once a week, for five weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 IV
Description: Intravenous injection, once a week, for five weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 IV
Description: Intravenous injection, once a week, for five weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRO044 IV
Description: Intravenous injection, once a week, for five weeks
Study: NCT02747940

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flunarizine and/or pregabalin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flunarizine and/or pregabalin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: flunarizine and/or pregabalin
Study: NCT01856686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BP22042013
Description: This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
Study: NCT04885478

Intervention type: OTHER
Intervention: Immune response monitoring , blood samples
Description: In both cohorts:~-SARS-CoV-2 IgG and IgM antibodies, ( Nucleocapside, Spike) in 8 visits during a year.~Infected HCW:~* Cytokines and T-Cell determination at baseline, 30, 60,180 days, 365 after positive test ( RT-PCR or SARS-CoV-2 antibodies )~* Covid-19 Symptoms, clinical monitoring

Intervention type: OTHER
Intervention: Immune response monitoring , blood samples
Description: In both cohorts:~-SARS-CoV-2 IgG and IgM antibodies, ( Nucleocapside, Spike) in 8 visits during a year.~Infected HCW:~* Cytokines and T-Cell determination at baseline, 30, 60,180 days, 365 after positive test ( RT-PCR or SARS-CoV-2 antibodies )~* Covid-19 Symptoms, clinical monitoring
Study: NCT01856686

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Description: the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
Study: NCT00259753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevasiranib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevasiranib
Study: NCT02470078

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phagenyx-Catheter, Phagenesis Limited, UK.
Description: Pharyngeal electrical stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: The intraluminal catheter (Phagenesis Ltd.) for pharyngeal electrical stimulation is placed. In the sham group the optimisation procedure was imitated as closely as possible to mitigate any bias or effect of time spent interacting with the patient during PES, but no current was applied. After this procedure 10 min of sham stimulation were delivered.
Study: NCT00259753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevasiranib
Study: NCT02684942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Study: NCT01319318

Intervention type: PROCEDURE
Intervention: Pars Plana Vitrectomy
Description: Pars plana vitrectomy performed in study eye on Day 0.
Study: NCT01594905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Entecavir + Tenofovir (MDR group)
Description: Entecavir 1.0mg + Tenofovir 300mg
Study: NCT02282007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual NPMP to the participants
Description: The participants in the intervention group will receive NPMP individually adjusted for six months. NPMP is not a standardized treatment approach, but individually adjusted to the individual patient according to their individual problems.
Study: NCT02684942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Study: NCT03276962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (Full dose)
Description: Participants will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).
Study: NCT02445079

Intervention type: OTHER
Intervention: This is an observational study only
Description: Observational study only

Intervention type: OTHER
Intervention: This is an observational study only
Description: Observational study only
Study: NCT02819726

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SAIT101
Description: 1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MabThera
Description: 1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituxan
Description: 1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
Study: NCT02829034

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranolazine
Description: Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
Study: NCT02684942

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
Study: NCT03276962

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (Full dose)
Description: Participants will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (Full dose)
Description: Participants will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (Full dose)
Description: Participants will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (1/5th dose)
Description: Participants will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01E (1/5th dose)
Description: Participants will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine
Description: Participants will receive intramuscular injection of rabies vaccine (0.1 ml).
Study: NCT00153868

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience \<1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations \>13.0 g/dL.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: darbepoetin alfa
Description: The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience \<1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations \>13.0 g/dL.
Study: NCT03775382

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Ascorbic acid will be infused into an antecubital vein using a IV infusion pump beginning with a priming bolus of 0.06 g Ascorbic Acid per kg fat-free mass dissolved in 100 ml of saline followed by a drip-infusion of 0.02 g Ascorbic Acid per kg fat-free mass dissolved in 30 ml of saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: Normal saline will be infused by the research nurse into an antecubital vein using an IV infusion pump.
Study: NCT03079869

Intervention type: DRUG
Group type: OTHER
Intervention: Ferric Citrate
Description: One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
Study: NCT00533585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY 43-9006
Description: Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 200 mg/m\^2 By Vein Over 3 Hours on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
Study: NCT03874585

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group counseling and nicotine replacement
Description: Participants will receive a 30-minute group smoking cessation counseling session and a supply of nicotine replacement.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group counseling, nicotine replacement, and text messaging support
Description: Participants will receive a 30-minute group smoking cessation counseling session, a supply of nicotine replacement, and the 6-week text messaging intervention to provide ongoing support for quitting
Study: NCT02120482

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combined apheresis
Description: Semiselective immunoadsorption combined with membrane filtration
Study: NCT00468312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two sprays in each nostril in the morning
Study: NCT02125617

Intervention type: DRUG
Intervention: Abiraterone
Description: 1000 mg/day

Intervention type: DRUG
Intervention: Prednisolone
Description: 10 mg/day
Study: NCT05799365

Intervention type: OTHER
Intervention: GMFCS-FR Turkish Adaptation
Description: GMFCS-FR Turkish Adaptation was applied the childrens mother, father and clinical physiotherapist.

Intervention type: OTHER
Intervention: GMFCS-FR Turkish Adaptation
Description: GMFCS-FR Turkish Adaptation was applied the childrens mother, father and clinical physiotherapist.
Study: NCT02829034

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth twice per day for a total of 26 weeks